On September 7, 2021 Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, reported that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the H.C, Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021 (Press release, Invectys, SEP 7, 2021, https://www.invectys.com/non-classe/invectys-inc-to-participate-in-the-2021-h-c-wainwright-23rd-annual-global-investment-conference-september-13-15-2021/ [SID1234587288]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Tyle will present on the topic titled "Novel Approaches to Tumor Eradication". Invectys, Inc focuses on a multi-modality approach to targeting HLA-G on tumor cells and also an approach with universal tumor antigen telomerase. The presentation is virtual and will be available on demand for the duration of the conference.
If you would like to set up a meeting, feel free to contact us at [email protected].